Trial Profile

A Randomised, Double-blind, Multiple Period Crossover Trial Comparing Insulin 454 and Insulin Aspart Premixes With Separately Injected, Simultaneous Doses of Insulin 454 and Insulin Aspart, Compared With Biphasic Insulin Aspart 30 (NovoMix 30) in Male Subjects With Type 1 and Type 2 Diabetes Mellitus

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Oct 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart (Primary) ; Insulin degludec (Primary) ; Insulin degludec/insulin aspart (Primary)
Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
Focus Pharmacodynamics; Pharmacokinetics
Sponsors Novo Nordisk

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com